NICE

Share

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99/m!

🗞️ NEWSNOW ESSENTIALS | Support independent news discovery ad free at just £2.99 a month!

NICE recommends Genmab’s cervical cancer treatment Pharmaceutical Field 21:25 Mon, 25 May

Pharmaceutical Field 21:25 Mon, 25 May

Cervical Cancer Pharma

J&J secures extended NICE approval for Darzalex following earlier refusal Pharmaceutical Technology 5d

Pharmaceutical Technology 5d

GSK’s Nucala secures NICE COPD endorsement Pharmaceutical Technology 12:18 Fri, 29 May

Pharmaceutical Technology 12:18 Fri, 29 May

Advertisement

Advertisement

'Every minute counts when it comes to new ovarian cancer treatment' BBC 14:50 Thu, 04 Jun

BBC 14:50 Thu, 04 Jun

AbbVie's migraine drug cleared for migraine attacks on NHS pharmaphorum 4d

pharmaphorum 4d

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer PMLiVE 11:05 Thu, 28 May

PMLiVE 11:05 Thu, 28 May

Cancer Cervical Cancer

Advertisement

Advertisement

Latest

Wednesday

AbbVie's migraine drug cleared for migraine attacks on NHS pharmaphorum 11:57 Wed, 10 Jun

Tuesday

J&J secures extended NICE approval for Darzalex following earlier refusal Pharmaceutical Technology 09:48 Tue, 09 Jun

In the last month

'Every minute counts when it comes to new ovarian cancer treatment' BBC 14:50 Thu, 04 Jun

AbbVie's ovarian cancer drug Elahere gets NHS green light pharmaphorum 09:02 Thu, 04 Jun

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy The Tribune, California 00:21 Thu, 04 Jun

GSK’s Nucala secures NICE COPD endorsement Pharmaceutical Technology 12:18 Fri, 29 May

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer PMLiVE 11:05 Thu, 28 May

NICE recommends Genmab’s cervical cancer treatment Pharmaceutical Field 21:25 Mon, 25 May

NICE changes stance on Genmab's cervical cancer drug pharmaphorum 09:58 Fri, 22 May

The US pharma deal is a crime against UK healthcare New Statesman 14:06 Wed, 20 May

Advertisement

Advertisement

Advertisement

Don't miss out! Get the day's top headlines delivered to your inbox

Advertisement

Advertisement